Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a 'Buy' rating on Axsome Therapeutics (NASDAQ:AXSM) and raises the price target from $95 to $100.
August 11, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a 'Buy' rating on Axsome Therapeutics and raises the price target from $95 to $100.
The raised price target by Mizuho indicates a positive outlook for Axsome Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100